Inspire Investing LLC increased its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 48.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,481 shares of the biotechnology company’s stock after purchasing an additional 2,105 shares during the period. Inspire Investing LLC’s holdings in Viking Therapeutics were worth $344,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of the business. Avoro Capital Advisors LLC bought a new position in shares of Viking Therapeutics in the first quarter valued at $294,380,000. Vanguard Group Inc. raised its holdings in shares of Viking Therapeutics by 44.7% in the 1st quarter. Vanguard Group Inc. now owns 7,785,724 shares of the biotechnology company’s stock worth $638,429,000 after acquiring an additional 2,403,820 shares during the last quarter. Perpetual Ltd acquired a new position in Viking Therapeutics during the 1st quarter valued at about $78,586,000. Hood River Capital Management LLC bought a new stake in Viking Therapeutics during the 1st quarter worth approximately $55,098,000. Finally, Westfield Capital Management Co. LP purchased a new stake in shares of Viking Therapeutics in the first quarter worth approximately $54,295,000. Institutional investors and hedge funds own 76.03% of the company’s stock.
Insider Buying and Selling
In other news, CEO Brian Lian sold 1,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $69.90, for a total transaction of $69,900.00. Following the sale, the chief executive officer now directly owns 2,354,927 shares in the company, valued at $164,609,397.30. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Viking Therapeutics news, Director J Matthew Singleton sold 10,300 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $69.50, for a total value of $715,850.00. Following the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $660,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Brian Lian sold 1,000 shares of Viking Therapeutics stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $69.90, for a total value of $69,900.00. Following the sale, the chief executive officer now owns 2,354,927 shares of the company’s stock, valued at approximately $164,609,397.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 516,671 shares of company stock valued at $33,810,813. Corporate insiders own 4.70% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Analysis on Viking Therapeutics
Viking Therapeutics Stock Performance
Shares of VKTX opened at $61.93 on Wednesday. Viking Therapeutics, Inc. has a fifty-two week low of $8.28 and a fifty-two week high of $99.41. The business has a 50-day moving average of $59.29 and a 200 day moving average of $62.88. The firm has a market cap of $6.83 billion, a P/E ratio of -66.59 and a beta of 1.00.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.06. During the same quarter in the prior year, the company earned ($0.19) earnings per share. As a group, research analysts predict that Viking Therapeutics, Inc. will post -1 earnings per share for the current fiscal year.
Viking Therapeutics Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also
- Five stocks we like better than Viking Therapeutics
- Market Cap Calculator: How to Calculate Market Cap
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is the Nikkei 225 index?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- NYSE Stocks Give Investors a Variety of Quality Options
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.